XOMA Royalty Corporation Common Stock (XOMA)
XOMA Royalty Corporation (XOMA) is a pharmaceutical company that specializes in acquiring and managing royalties from innovative biopharmaceutical products. The company focuses on generating revenue through royalties and licensing agreements derived from its portfolio of biotechnology innovations. It provides investors with exposure to the success of various therapeutic products developed by partner companies in the biotech and pharmaceutical sectors.
Company News
XOMA Royalty and LAVA Therapeutics amended their share purchase agreement, reducing the initial cash amount per share to $1.04 and introducing a contingent value right (CVR). The tender offer has been extended to November 12, 2025, with the acquisition expected to close in Q4 2025.
XOMA Royalty Corporation has extended its tender offer to purchase LAVA Therapeutics shares until October 17, 2025, with a cash payment and contingent value right per share. The proposed acquisition is expected to close in Q4 2025, subject to customary closing conditions.
XOMA Corporation, a biotechnology company, announced that it will change its name to XOMA Royalty Corporation, effective July 10, 2024. The rebranding reflects the company's focus on pharmaceutical royalties.
XOMA Corporation operates as a biotechnology royalty aggregator, acquiring economic rights to milestones and royalties from approved or clinical-stage drugs.
Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
